Inventor
Rajiv PANWAR
Inventor
US
Overview
Patents· 6 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07KPeptides25%
Y02ATechnologies for adaptation to climate change10%
B01JChemical or physical processes, e.g. catalysis or colloid chemistry5%
C07CAcyclic or carbocyclic compounds5%
C10GCracking hydrocarbon oils5%
PatentTitleYear
12,595,284Amatoxin antibody-drug conjugates and uses thereof202612,570,756Methods of use of anti-CD45 antibodies and conjugates thereof202612,209,135Anti-CD45 antibodies and conjugates thereof202511,958,908Compositions and methods for the depletion of CD117+ cells202411,572,411Anti-CD117 antibodies and conjugates202311,318,452Single step process for the simultaneous production of aromatics, naphthenics and isoparaffins using transition metal functionalized zeolite based catalyst2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022Patents assigned to COUNCIL SCIENT IND RES (1)· patent assignee history
2022Based in IN· patent location history
2023Patents assigned to MAGENTA THERAPEUTICS INC (1)· patent assignee history
2023–2026Based in US· patent location history
2024Patents assigned to CRISPR THERAPEUTICS AG (1)· patent assignee history
2026Patents assigned to HEIDELBERG PHARMA RES GMBH (1)· patent assignee history
2026Patents assigned to REGENERON PHARMA (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| COUNCIL SCIENT IND RES | 1 | 2022 |
| CRISPR THERAPEUTICS AG | 1 | 2024 |
| HEIDELBERG PHARMA RES GMBH | 1 | 2026 |
| MAGENTA THERAPEUTICS INC | 1 | 2023 |
| REGENERON PHARMA | 1 | 2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 5 | 2023–2026 |
| IN | 1 | 2022 |